Given the primary role of increased hepatic gluconeogenesis in the pathogenesis of hyperglycemia in insulin resistance and type 2 diabetes, new drugs aimed at targeting OGG1 specifically to mitochondria may propose a novel form of treatment for metabolic disease. The gene discussed is OGG1; the disease is type 2 diabetes mellitus.